Beta Bionics price target lowered to $18 from $25 at Truist

Truist lowered the firm’s price target on Beta Bionics (BBNX) to $18 from $25 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results in MedTech. The firm expects Q1 performances to be in line or better than what feels like an anxious investor sentiment around Q1 volumes, the analyst tells investors in a research note. A discount in the stock valuation reflects the slowdown in the company’s new patient starts momentum, though the firm believes this will prove transient, Truist added.